At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Ralinepagdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Extension Study of Ralinepag in Patients With Pulmonary Arterial Hypertension
In Brief
A Phase 2 clinical trial evaluating Ralinepag for Pulmonary Arterial Hypertension. Completed, enrolled 45 participants across 46 sites in 10 countries.
Detailed Summary
This study was an open-label extension study to determine the long-term safety and tolerability of ralinepag in subjects with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) who have completed Study APD811-003, or who were assigned to receive placebo and were discontinued due to clinical worsening.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesAustralia, Bulgaria, Czechia, Hungary, Poland, Romania, Serbia, Slovakia, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartJul 2015
Primary CompletionMar 2021
TodayJul 2026
First PostedOct 31, 2014
Enrollment StartJul 8, 2015
Primary CompletionMar 29, 2021
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 11.7 years ago
Interventions
Ralinepagdrug
Active